(RTTNews) - Sempra Infrastructure, a subsidiary of utility company, Sempra (SRE), Monday announced that it has appointed Bhavesh Patel as its incoming chief executive officer as he will assume this role upon the closing of a KKR-led consortium's acquisition of a majority ownershi
(RTTNews) - Sempra Infrastructure, a subsidiary of utility company, Sempra (SRE), Monday announced that it has appointed Bhavesh Patel as its incoming chief executive officer as he will assume this role upon the closing of a KKR-led consortium's acquisition of a majority ownershi
If you owned Sprott Junior Copper Miners ETF (NASDAQ:COPJ) on Friday morning, you watched it open near $45.37 and close at $40.37, an 11% single-day tumble on June 5, 2026. A $10,000 stake at Thursday’s close became roughly $8,900 by Friday’s bell. For a fund that returned 93% over the prior twelve months, this was ... Broadcom Sneezed and COPJ Investors Lost 11% In A Day And Learned That Copper’s...
If you owned Sprott Junior Copper Miners ETF (NASDAQ:COPJ) on Friday morning, you watched it open near $45.37 and close at $40.37, an 11% single-day tumble on June 5, 2026. A $10,000 stake at Thursday’s close became roughly $8,900 by Friday’s bell. For a fund that returned 93% over the prior twelve months, this was ... Broadcom Sneezed and COPJ Investors Lost 11% In A Day And Learned That Copper’s AI Story Has a Pause Button
Walter Cicchetti/iStock Editorial via Getty Images By Shannon L. Saccocia and Joe Amato The SpaceX ( SPCX ) IPO is without precedent in scale and structure. Its implications for markets, indices and portfolios extend well beyond the deal itself. A pipeline of mega-cap private companies is headed toward public markets, potentially reshaping the equity landscape when they arrive. SpaceX, Elon Musk's...
Walter Cicchetti/iStock Editorial via Getty Images By Shannon L. Saccocia and Joe Amato The SpaceX ( SPCX ) IPO is without precedent in scale and structure. Its implications for markets, indices and portfolios extend well beyond the deal itself. A pipeline of mega-cap private companies is headed toward public markets, potentially reshaping the equity landscape when they arrive. SpaceX, Elon Musk's aerospace, satellite communications and artificial intelligence (AI) company, is the first. It has a target IPO valuation of around $1.8 trillion, raising capital of up to $75 billion in the process. To put that in context: oil major Saudi Aramco’s ( ARMCO ) 2019 offering, the largest in history, raised $25.6 billion on a $1.7 trillion valuation, while Alibaba’s ( BABA ) 2014 deal, long the benchmark for technology IPOs, raised $21.8 billion and was valued at $170 billion. The SpaceX IPO is 10 times larger than the latter, and we expect strong retail demand for the shares. But it will not be the only high-value public offering this year: Anthropic ( ANTHRO ) recently filed with the U.S. Securities and Exchange Commission, and we expect OpenAI ( OPENAI ) to be coming soon as well. Anthropic and OpenAI raised capital in private offerings earlier this year at valuations approaching $1 trillion. This wave of listings will dramatically reshape the indices most investors track and further test the depth of investor demand for mega-cap tech following the record $85 billion equity offering last week from Alphabet, Google’s parent. Three Businesses, One Valuation Following its February 2026 merger with xAI, SpaceX is effectively three businesses: a launch operation anchored by its Falcon 9 rocket—which commands approximately 90% of global commercial launch market share—Starlink, its satellite internet company targeting about 100 million subscribers and $140 billion in revenue by 2030 (according to the IPO underwriters), and xAI, its artificial intelligence subsidiary. By 2030, xAI ...
Honeywell International ( HON ) reaffirmed its full-year 2026 financial guidance on Monday and outlined preliminary expectations for the company that will remain after the planned June 29 spin-off of its aerospace division. Shares were little changed in premarket trading, erasing an earlier decline. The industrial conglomerate said it continues to expect 2026 sales of $38.8 billion to $39.8 billio...
Honeywell International ( HON ) reaffirmed its full-year 2026 financial guidance on Monday and outlined preliminary expectations for the company that will remain after the planned June 29 spin-off of its aerospace division. Shares were little changed in premarket trading, erasing an earlier decline. The industrial conglomerate said it continues to expect 2026 sales of $38.8 billion to $39.8 billion, with organic revenue growth of 3% to 6%. Adjusted earnings per share are projected at $10.35 to $10.65, representing growth of 6% to 9% from the prior year. The company also maintained its forecast for free cash flow of $5.3 billion to $5.6 billion. Honeywell disclosed the updated outlook ahead of an investor conference call and its Investor Day scheduled for June 11. The aerospace separation is part of a broader restructuring effort that will leave the remaining company operating under the name Honeywell Technologies. Investors have been closely watching the transaction as industrial companies increasingly pursue breakups to simplify operations and unlock shareholder value. The guidance provides an early look at the earnings power and cash generation prospects of the post-spin business. For Honeywell Technologies, the company forecast 2026 sales of $19.9 billion to $20.2 billion and organic growth of 2% to 3%. Segment margins are expected to range from 19.8% to 20.3%, reflecting expansion of 220 to 270 basis points from 2025 levels. Adjusted earnings per share for the remaining company are projected at $3.95 to $4.15, representing growth of 22% to 28%, while free cash flow is expected to be about $2.0 billion. The outlook excludes results from the aerospace business and incorporates the planned sales of Productivity Solutions and Services and Warehouse and Workflow Solutions, both of which Honeywell expects to complete by the fourth quarter. The forecast also includes estimated contributions from the acquisition of Johnson Matthey's Catalyst Technologies business, which...
Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with t...
Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with two new stores opened in the third quarter of 2025. CEO Stephanie Pugliese said customers are responding positively to core products, seasonal prints and patterns, and the newest marketing campaign. The retailer saw gross margin expand by 540 basis points to 57.4% of sales during the quarter. The increase in gross margin rate was primarily driven by an increase in average unit retail prices from reduced promotional activity, coupled with an improvement in product costs from the direct-to-factory sourcing initiative, partially offset by tariff costs. Non-GAAP EPS was reported at -$0.20 vs. -$0.39 consensus and -$0.44 a year ago. On the balance sheet, Duluth Holdings ( DLTH ) ended the quarter with $6.1M of cash and cash equivalents, $62.3M of net working capital, and $6.0M in outstanding debt on the $100.0M asset-based lending facility, resulting in approximately $100M of net liquidity. Looking ahead, Duluth Holdings ( DLTH ) sees FY26 sales landing in a range of $540M to $560M (midpoint $550M) vs. the consensus estimate of $555.6M. "O ur focus remains on delivering the core, high-quality, solution-based products that resonate most with our customers and creating an exceptional experience," stated Pugliese. Shares of Duluth Holdings ( DLTH ) were up 1.8% in premarket trading to $3.38 vs. the 52-week range of $1.82 to $4.66. More on Duluth Holdings Duluth Holdings Still Needs To Prove Itself Duluth Holdings: Showing Signs Of Stabilization Duluth Holdings Inc. (DLTH) Q4 2025 Earnings Call Transcript Duluth Holdings Non-GAAP EPS of -$0.20 beats by $0.19, revenue of $98.59M beats...
(RTTNews) - Brady Corp. (BRC), a developer and manufacturer of specialty products, on Monday announced that it appointed current board member Vineet Nargolwala as Chief Executive Officer, effective June 8.
(RTTNews) - Brady Corp. (BRC), a developer and manufacturer of specialty products, on Monday announced that it appointed current board member Vineet Nargolwala as Chief Executive Officer, effective June 8.
Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales milestones, for a total potential consideration of up to $2B, subject to customary closing adjustments. The proposed acquisition would add VGA0...
Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales milestones, for a total potential consideration of up to $2B, subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease. The drug has advanced into a Phase 3 study designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of von Willebrand disease. It has received fast track, orphan drug, rare pediatric disease, and breakthrough therapy designations from the U.S. Food and Drug Administration. “VGA039 fits directly into our strategy of building a top-tier growth company for the future,” said Bill Meury, CEO of Incyte. “It is a first-in-class, Phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas – hematology. The transaction has all of the attributes we look for in business development opportunities.” The transaction is an equity acquisition and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review resulting in an expected R&D charge of approximately $1.25B that will be included in third quarter and full year 2026 GAAP and non-GAAP results. More on Incyte Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Incyte: Strong Business, But Risks Remain Incyte nears $2B deal for blood diso...
Volato Group ( SOAR ) has signed a definitive agreement for a $2.2M strategic equity investment. The restricted common stock placement was led by medical technology firm Catheter Precision ( VTAK ) alongside other institutional technology investors. The capital injection significantly strengthens Volato’s balance sheet following the termination of its previously announced transaction with M2i Glob...
Volato Group ( SOAR ) has signed a definitive agreement for a $2.2M strategic equity investment. The restricted common stock placement was led by medical technology firm Catheter Precision ( VTAK ) alongside other institutional technology investors. The capital injection significantly strengthens Volato’s balance sheet following the termination of its previously announced transaction with M2i Global. Management confirmed that the M2i termination will not disrupt its ability to pursue milestones under its accepted NYSE American compliance plan. The capital from this round will back Volato’s core strategic shift toward the artificial intelligence ecosystem, specifically targeting potential mergers and acquisitions (M&A) across AI software, data infrastructure, compute, and power generation sectors. Volato revealed it has already received two unsolicited, non-binding letters of intent regarding potential transactions involving AI data center infrastructure and dedicated power generation assets. The company already operates Parslee, an AI software platform specializing in document intelligence, and is actively developing Volato AI to deploy specialized AI agents into the aviation sector. Following the placement, Catheter Precision becomes Volato’s largest shareholder. The strategic investment remains subject to customary closing conditions, including the authorization of a supplemental listing application filed by Volato with the NYSE American exchange. More on Catheter Precision, Volato Group Volato Group receives NYSE American acceptance of compliance plan Volato Group uses full ATM capacity; convertible debt hits zero ahead of M2i merger Historical earnings data for Catheter Precision Financial information for Catheter Precision Financial information for Volato Group
(RTTNews) - Shares of Tate & Lyle Plc were gaining around 14 percent on the London Stock Exchange after the British sweetener and food solutions firm announced Monday its agreement to a 595 pence per share all-cash deal to be bought by U.S. food ingredients maker Ingredion Inc. T
(RTTNews) - Shares of Tate & Lyle Plc were gaining around 14 percent on the London Stock Exchange after the British sweetener and food solutions firm announced Monday its agreement to a 595 pence per share all-cash deal to be bought by U.S. food ingredients maker Ingredion Inc. T
U.S. government acquires an ownership stake in Intel (NasdaqGS:INTC) under the Trump administration. Transaction is part of a broader federal approach to take equity stakes in key AI and semiconductor companies. Move goes beyond prior grants and subsidies, introducing direct public sector participation in Intel's capital structure. Intel, traded on the NasdaqGS under the ticker INTC, is a major U....
U.S. government acquires an ownership stake in Intel (NasdaqGS:INTC) under the Trump administration. Transaction is part of a broader federal approach to take equity stakes in key AI and semiconductor companies. Move goes beyond prior grants and subsidies, introducing direct public sector participation in Intel's capital structure. Intel, traded on the NasdaqGS under the ticker INTC, is a major U.S. semiconductor and AI hardware company. Federal ownership adds a new layer to an already high...